Related by context. All words. (Click for frequent words.) 67 R#/MEM # 65 rNAPc2 65 ENMD # 65 PRT# 64 JAK inhibitor 64 PEG SN# 64 HCD# [002] 63 pharmacodynamic effects 63 rFIXFc 63 TRO# 63 Sym# 63 Triolex 63 PDE4 inhibitor 63 XmAb# 63 GAMMAGARD 63 AP# [003] 63 Traficet EN 63 TACI Ig 63 phase IIa clinical 63 HQK 62 Archexin 62 mertansine 62 Factor VIIa 62 Factor IX 62 Azedra 62 MEK inhibitor 62 HGS ETR1 62 preclinically 62 TG# [003] 62 subcutaneous formulation 62 CR# vcMMAE 62 HspE7 62 immunomodulator 62 Alocrest 62 RSD# 62 Phase #b/#a trial 62 Tyrima 62 registrational trial 61 urocortin 2 61 AEG# 61 Androxal TM 61 Symadex 61 humanized anti 61 Panzem 61 cilengitide 61 elotuzumab 61 INCB# [001] 61 Phase Ib study 61 Omacetaxine mepesuccinate 61 Mipomersen 61 Capesaris 61 CCX# 61 PSMA ADC 61 Amplimexon 60 YONDELIS 60 Cardio Vascu Grow 60 ZOLINZA 60 HuMax EGFr 60 ISIS # 60 volociximab 60 PXD# 60 MDV# 60 PRX# 60 angiogenesis inhibitor 60 oral prodrug 60 Bezielle 60 E1 INT TM 60 REG1 60 corticosteroid dexamethasone 60 Onconase 60 RAV# 60 GALNS 60 proteasome inhibitor 60 huN# DM1 60 IRX 2 60 Imprime PGG 60 Dapagliflozin 60 NGX# 60 generation purine nucleoside 60 somatostatin analogue 60 dacetuzumab 60 Tarvacin TM 60 TREANDA 60 MAP# 60 Phenoptin 59 INCB# [002] 59 Nasulin 59 pomalidomide 59 Fx #A 59 Carfilzomib 59 bardoxolone 59 forodesine 59 HuLuc# 59 OXi# 59 OMP #M# 59 HCV protease inhibitor 59 Chrysalin 59 pertuzumab 59 MGd 59 IMA# 59 PI3K inhibitor 59 Vidofludimus 59 Laquinimod 59 Plicera 59 DB# [003] 59 Phase Ib 59 Phase 1a clinical 59 PD LID 59 Genz # 59 CIMZIA TM 59 VA# [002] 59 VEGF Trap 59 HuMax CD# 59 alvespimycin 59 PRTX 59 epothilone 59 pan HDAC inhibitor 59 vidofludimus 59 Neurodex 59 otelixizumab 59 enzastaurin 59 DOS# 59 Personalized Immunotherapy 59 Alzhemed TM 59 RhuDex ® 59 #I TM# 59 Bendavia 59 CEQ# 59 Phase Ib clinical 59 Pimavanserin 59 orally bioavailable 59 Panzem R NCD 59 IDX# 59 CG# [003] 59 Tesetaxel 59 Glufosfamide 59 CDK inhibitor 59 C1 INH 59 glufosfamide 58 MultiStem 58 MGCD# [001] 58 RDEA# 58 nucleoside analog 58 solithromycin 58 pralatrexate 58 eniluracil 58 Debio 58 ostarine 58 PS# [001] 58 Marqibo 58 GSK# [002] 58 Corlux 58 Asentar 58 polymerase inhibitor 58 teduglutide 58 Phase 1b 58 EndoTAG TM -1 58 Phase 2a trial 58 AVN# [001] 58 cannabinor 58 favorable pharmacokinetic profile 58 selective modulator 58 BAY #-# 58 immune modulator 58 thalidomide Thalomid 58 humanized antibody 58 HCV protease 58 thymalfasin 58 elacytarabine 58 Pralatrexate 58 Dasatinib 58 OncoGel 58 dose escalation Phase 58 erlotinib Tarceva ® 58 DEB# 58 teplizumab 58 Tarvacin 58 OHR/AVR# 58 atacicept 58 metaglidasen 58 riociguat 58 PNT# 58 PRX # 58 IMGN# 58 vascular disrupting agent 58 refractory gout 58 Apoptone 58 DXL# 58 NPC 1C 58 ATL# [001] 58 Actilon 58 THR beta agonist 58 Phase 1b trial 58 INT# [002] 58 glucokinase activator 58 MAGE A3 ASCI 58 omacetaxine 58 subcutaneously administered 58 GHRH 58 targeted antifolate 58 Amigal 58 luteinizing hormone releasing 58 CD# antibody [001] 58 PLK1 SNALP 58 pharmacokinetic profile 58 anticancer agent 58 torezolid 58 TELINTRA 58 LymphoStat B TM 58 huC# DM4 58 Clolar ® 58 JAK inhibitors 58 nalbuphine ER 58 Aclidinium 58 ZACTIMA 58 Luteinizing Hormone Releasing Hormone 58 DermaVir Patch 58 Virulizin ® 57 peginesatide 57 TRIOLEX 57 GRNVAC1 57 ELACYT 57 Annamycin 57 phase IIb clinical 57 sodium glucose cotransporter 57 alfimeprase 57 MAXY G# 57 axitinib 57 Omacetaxine 57 Sapacitabine 57 PEGPH# 57 dextromethorphan quinidine 57 methylnaltrexone 57 Angiocept 57 NVA# 57 teriflunomide 57 deforolimus 57 Proxinium TM 57 OncoVEX GM CSF 57 liposomal formulation 57 tezampanel 57 PrevOnco ™ 57 sapacitabine 57 imatinib Gleevec ® 57 HuMax CD4 57 OncoVEX 57 Golimumab 57 CTCE 57 multicenter Phase II 57 tafamidis 57 XL# [003] 57 Phase 2b study 57 samalizumab 57 Phase III Pivotal 57 Allovectin 7 R 57 custirsen 57 Ceflatonin 57 veltuzumab 57 targeted radiotherapeutic 57 Xanafide 57 phase 2a 57 LY# [003] 57 leukemia AML 57 Phase Ib II 57 torezolid phosphate 57 Protexia R 57 GLP toxicology studies 57 adecatumumab 57 decitabine 57 Fc fusion protein 57 visilizumab 57 MYDICAR ® 57 ALN TTR 57 CoFactor 57 Dacogen injection 57 Squalamine 57 Exherin TM 57 T#I [002] 57 generation antisense 57 HDACi 57 Quinamed 57 nucleotide analog 57 lead Aganocide compound 57 Ostarine 57 NP2 Enkephalin 57 IMC A# 57 CCR9 antagonist 57 Troxatyl 57 ORENCIA ® 57 depsipeptide 57 ONTAK 57 APOPTONE 57 Glypromate 57 ongoing Phase 1b 57 PF # [001] 57 PKC# 57 factor Xa 57 CBLC# 57 XL# XL# 57 ADVEXIN 57 CD3 monoclonal antibody 57 MAb 57 dasatinib Sprycel ® 57 Enzastaurin 57 SAR# [002] 57 Guanilib 57 GRN#L 57 crizotinib PF # 57 administered subcutaneously 57 Phase IIa trials 57 ularitide 57 BZL# 57 beta 1a 57 Vilazodone 57 ELND# 57 pradefovir 57 Panzem R 57 SinuNase ™ 57 R roscovitine 57 ZYBRESTAT 57 ELND-#/AZD-# 57 AZD# 57 HGS# 57 cathepsin K inhibitor 57 gamma secretase inhibitor 57 eprotirome 57 JAK3 57 BiTE 57 HE# [002] 57 PSN# [002] 57 PEG PAL 57 PROMACTA 57 Cloretazine R VNP#M 57 amifampridine phosphate 56 selectively binds 56 Delafloxacin 56 ocular formulation 56 elesclomol 56 Maribavir 56 SCH # 56 mapatumumab 56 Ocrelizumab 56 Azixa 56 vemurafenib 56 Reolysin 56 PEG Interferon lambda 56 Phase IIB 56 seliciclib CYC# 56 RSD# oral 56 HSP# inhibitor 56 eltrombopag 56 PARP inhibitor 56 S/GSK# 56 Ataluren 56 Phase IIa trial 56 ON #.Na 56 Amrubicin 56 Phase 2a 56 trastuzumab DM1 T DM1 56 ganetespib 56 Zerenex 56 uricase 56 tanespimycin 56 novel oral anticoagulant 56 virus HCV protease inhibitor 56 CCX# B 56 FluCide 56 preclinical efficacy 56 histone deacetylase HDAC inhibitor 56 SYN# 56 Irinotecan 56 immunotherapeutic agent 56 indibulin 56 Prodarsan ® 56 Targretin 56 alemtuzumab Campath 56 trodusquemine 56 Pharmacokinetics PK 56 pharmacodynamic profile 56 oral antiviral 56 RH1 56 anticancer compound 56 Insegia 56 maturation inhibitor 56 CA4P 56 Revimmune 56 TBC# 56 Phase IIIb clinical 56 Bortezomib 56 PEGylated 56 KNS # 56 FVIIa 56 protein kinase inhibitor 56 LAS# [002] 56 Chemophase 56 Azedra TM 56 Fodosine 56 TG# [001] 56 ATL# [002] 56 dose escalation trial 56 Initiated Phase 56 Phase 2b trial 56 nonclinical studies 56 CD# monoclonal antibody 56 SAR# [004] 56 IFN α 56 NEUMUNE 56 Trastuzumab 56 sodium thiosulfate STS 56 CYC# 56 nitazoxanide 56 MEK inhibitors 56 brivaracetam 56 HDAC Inhibitor 56 pharmacokinetic PK 56 CRLX# 56 topical ophthalmic 56 selective adenosine 56 IIa trial 56 TKM ApoB 56 dirucotide 56 Ophena TM 56 LHRH antagonist 56 PROCHYMAL 56 ALN RSV# 56 rhMBL 56 SLx 56 TriRima 56 Dual Opioid 56 MLN# 56 Vitaxin 56 Oral NKTR 56 cediranib 56 Vicinium TM 56 budesonide foam 56 anti leukemic 56 hypoxia activated prodrug 56 Velcade bortezomib 56 CCR5 antagonist 56 radiation sensitizer 56 Phase IIb clinical trials 56 rFVIIIFc 56 velafermin 56 Neulasta ® 56 aurora kinase 56 RG# [001] 56 ARIKACE ™ 56 tolevamer 56 cynomolgus monkeys 56 IND submission 56 Phase IIa clinical 56 selective androgen receptor modulator 56 PEP# [003] 56 trial evaluating PRX# 56 Phase #/#a 56 alkylating agent 56 pharmacokinetic PK study 56 NOX E# 56 E2F Decoy 56 Surfaxin LS 56 LymphoStat B 56 belinostat 56 Octreotide 56 telomerase therapeutic 56 gefitinib Iressa 56 investigational humanized monoclonal antibody 56 TLK# 56 Nanobody 56 AKT inhibitor 56 PDX pralatrexate 56 nab paclitaxel 56 eculizumab 56 tipifarnib 56 Lixivaptan 56 OncoVex 56 L BLP# 56 Simulect 56 MOZOBIL 55 Cannabinor 55 PEGylated Fab fragment 55 EGFR HER2 55 AZILECT R 55 ONCONASE R 55 AeroLEF TM 55 histone deacetylase inhibitor 55 proteasome inhibitors 55 Alfimeprase 55 ocrelizumab 55 Catena ® 55 intranasal formulation 55 antisense inhibitors 55 CTAP# Capsules 55 orally administered inhibitor 55 Synavive 55 Zybrestat 55 sargramostim 55 EOquin TM 55 Receptor Antagonists 55 Serdaxin 55 JAK2 55 Aurora Kinase 55 Viprinex 55 sodium glucose transporter 55 selective agonist 55 obatoclax 55 Hsp# inhibitor 55 ASONEP 55 talabostat 55 GED aPC 55 NEUGENE 55 cytotoxin 55 bortezomib Velcade ® 55 ALN VSP 55 Blinatumomab 55 Factor Xa inhibitor 55 ALGRX 55 perifosine 55 ataluren 55 Tarmogen 55 neratinib 55 GLPG# 55 castration resistant prostate cancer 55 antibody MAb 55 ALN TTR# 55 lorvotuzumab mertansine 55 delafloxacin 55 tamibarotene 55 #ME# 55 Phase IIb trials 55 pegylated interferons 55 recombinant factor VIIa 55 chemotherapeutic drug 55 TH# [003] 55 including eniluracil ADH 55 ORMD 55 Deforolimus 55 tiapamil 55 PDE# inhibitors 55 mTOR inhibitors 55 OMP #R# 55 lintuzumab 55 Vascugel 55 TMC# [002] 55 Aurora kinase 55 RhuDex 55 zileuton 55 Crofelemer 55 systemically administered 55 gonadotropin releasing hormone GnRH 55 Cimzia TM 55 GW# [003] 55 EOquin 55 DDP# 55 PNP inhibitor 55 midstage clinical 55 PI3K/Akt pathway inhibitor 55 velafermin belinostat 55 fosbretabulin 55 clofarabine 55 Chemokine 55 Treanda 55 VAPRISOL 55 radiolabeled 55 H#N# VLP vaccine 55 prucalopride 55 pharmacodynamic PD 55 GSK# [001] 55 TRV# [001] 55 Solulin 55 Natalizumab 55 orally dosed 55 CYT# potent vascular disrupting 55 Anavex #-# 55 JAK1 55 IMP# 55 relapsed multiple myeloma 55 Phase IIb clinical 55 Shigamabs ® 55 REP# 55 randomized controlled Phase 55 Aliskiren 55 Atu# 55 multiple ascending dose 55 PLX# 55 Voreloxin 55 Janus Kinase 55 HGS ETR2 55 telaprevir VX 55 Elotuzumab 55 aflibercept 55 mGluR2 NAM 55 nanoviricide drug 55 BCX# 55 selective immunoproteasome inhibitor 55 receptor tyrosine kinase inhibitor 55 pharmacodynamic 55 ruxolitinib 55 IgG1 antibody 55 PSN# [001] 55 Boceprevir 55 Stimuvax 55 Arimoclomol 55 PANVAC VF 55 phase IIb 55 PCK# 55 histone deacetylase HDAC 55 dosing cohort 55 acyclovir Lauriad R 55 BRIM2 55 Q#IR 55 tesmilifene 55 Cethrin R 55 alpha interferon 55 Aplidin 55 ILLUMINATE 55 rindopepimut 55 Saforis 55 humanized monoclonal antibody 55 daclizumab 55 FLT3 55 IFN beta 55 FOLOTYN ® 55 Initiate Phase 55 vascular disrupting 55 Nuvion 55 HCV polymerase 55 Curaxin 55 IND enabling 55 receptor blocker 55 registrational 55 BRAF inhibitor 55 alefacept 55 Phase 2a clinical 55 Tamibarotene 55 Ramoplanin 55 INC# 55 CYT# 55 TELCYTA 55 cancer immunotherapies 55 Tanespimycin 55 bevacizumab Avastin ® 55 calcipotriene 55 Spiegelmer ® 55 davunetide intranasal AL 55 ALV# 55 Canvaxin TM 55 next generation URAT1 55 JAK2 inhibitor 55 abiraterone acetate 55 MYDICAR 55 murine monoclonal antibody 55 PEG interferon 55 GRN# 55 Iloperidone 55 Hsp# Inhibitor 55 ONCONASE 55 5 Fluorouracil 55 Lubiprostone 55 basiliximab 55 CD# CEA 55 dose cohort 54 APD# 54 CORT # 54 XmAb 54 CTA# Injection 54 Aganocide 54 bendamustine 54 incyclinide 54 JAK2 inhibitors 54 ANAVEX #-# [003] 54 Albuferon 54 KRN# 54 INS# [001] 54 Phase 2a Clinical Trial 54 Telintra 54 Talabostat 54 initiate Phase 1b 54 CCR2 54 seliciclib 54 omecamtiv mecarbil 54 Daclizumab 54 metastatic malignant 54 Cethrin 54 Preclinical studies suggest 54 renin inhibitors 54 RP# [002] 54 bicifadine 54 Ozarelix 54 Desmoteplase 54 immunomodulatory therapy 54 dalbavancin 54 TLR9 agonist 54 pharmacodynamic properties 54 Lpathomab 54 targeting CD# 54 ixabepilone 54 AzaSite Plus 54 generation antisense inhibitor 54 PREOS 54 cell lymphoma CTCL 54 Clevudine 54 metastatic hormone refractory 54 antisense drug 54 DAVANAT 54 UPLYSO 54 VitiGam 54 alagebrium 54 JAK3 inhibitor 54 vilazodone 54 potent inhibition 54 Privigen 54 maximally tolerated dose 54 2 methoxyestradiol 54 reversible inhibitor 54 Fibrillex TM 54 IIa trials 54 imetelstat 54 Anticalin R 54 OvaRex R 54 AQ4N 54 antitumor activity 54 Aflibercept 54 hormone LHRH antagonist 54 mAb 54 nanoviricides 54 rxRNA 54 demonstrated antitumor activity 54 Telatinib 54 pediatric acute lymphoblastic 54 gastrointestinal stromal tumors GIST 54 CDDO Im 54 ESBA# 54 baminercept 54 SPC# [001] 54 AEGR 54 Liposomal 54 diabetic neuropathic pain 54 oral JAK1 54 aspirin clopidogrel 54 phase IIb study 54 Phase IIa 54 DU #b 54 EZN 54 gemcitabine cisplatin 54 Alferon N 54 docetaxel Taxotere ® 54 Darusentan 54 Decitabine 54 Phase 2a clinical trials 54 inhibitor RG# 54 LAF# 54 cetuximab Erbitux ® 54 Vidaza azacitidine 54 CB2 selective receptor agonist 54 LEUKINE 54 HER2 positive metastatic breast 54 omacetaxine mepesuccinate 54 epratuzumab 54 INGN 54 Tarceva TM 54 Bicifadine 54 Phase 1a 54 alemtuzumab MS 54 non nucleoside HCV 54 Pemetrexed 54 romidepsin 54 denufosol 54 Litx 54 bafetinib 54 Angiotensin Converting Enzyme 54 ISF# 54 novel peptide 54 selective inhibitor 54 viral kinetic 54 Cetrorelix 54 Phase 1b clinical trials 54 NeuroVax 54 CRx 54 BiTE antibody 54 regorafenib 54 synthetic anti infective 54 ICA # 54 Antigenics QS 54 lesinurad 54 Elvitegravir 54 Trizytek 54 Aurexis 54 ibudilast 54 ApoB SNALP 54 GV# [001] 54 iSONEP 54 novel histone deacetylase 54 AAG geldanamycin analog 54 ImmunoVEX HSV2 54 lipopeptide 54 sitaxsentan 54 docetaxel Taxotere R 54 thrombin receptor 54 antiangiogenic agent 54 alpha#beta# integrin 54 synthetic retinoid 54 valopicitabine 54 Solazed 54 Perifosine 54 omega interferon 54 CRMD# 54 ritonavir boosted 54 Interferon alfa 54 BAL# [002] 54 Inosine 54 BEMA TM Fentanyl 54 Phase Ib clinical trials 54 Phase 2b clinical trials 54 anti CD3 54 sumatriptan DosePro 54 RELOVAIR ™ 54 laquinimod 54 HCV replicon 54 Fluorouracil 54 anti CD3 monoclonal 54 ARIKACE 54 Panzem NCD 54 ENMD 54 Myocet 53 Ceplene/IL-2 53 MEK inhibitor RDEA# 53 Pruvel 53 DermaVir 53 GFT# 53 HepeX B TM 53 aldehyde dehydrogenase ALDH2 deficiency 53 Ophena 53 mipomersen 53 multi kinase inhibitor 53 Denufosol 53 Phase III Clinical Trials 53 Prodarsan 53 NXL# 53 Safinamide 53 confirmatory Phase III 53 Advexin 53 Novolimus 53 K ras 53 investigational hepatitis C 53 isoform selective 53 Zolinza 53 FavId 53 Exelixis XL# 53 Anticalin 53 triphendiol 53 placebo controlled Phase 53 Ceflatonin R 53 defensin mimetic antibiotic 53 antiangiogenic therapy 53 siRNAs targeting 53 drug GAP #B# 53 Diamyd ® 53 lomitapide 53 preclinical compounds 53 TransVax tm 53 EndoTAG 53 hematological cancers 53 cetuximab Erbitux R 53 tramiprosate Alzhemed TM 53 Exelixis compounds 53 ZD# [001] 53 hematological tumors 53 iniparib 53 Phase 1b clinical 53 pegylated liposomal doxorubicin 53 bortezomib Velcade 53 ProLindac 53 adecatumumab MT# 53 resminostat 53 aprepitant 53 Aganocide ® 53 NEUGENE antisense 53 HuMax TAC 53 entinostat 53 KSP inhibitor 53 proteasome inhibitor bortezomib 53 Microplasmin 53 ALK inhibitor 53 mecamylamine 53 Pivotal Phase 53 Survivin antagonist 53 isavuconazole 53 Akt inhibitor 53 HIV integrase inhibitor 53 ProMune 53 maribavir 53 Toraymyxin TM 53 recombinant subunit vaccine 53 oral Factor Xa 53 Sphingomab TM 53 Menerba 53 sorafenib Nexavar 53 Stedivaze 53 SinuNase 53 MB# [004] 53 GVAX 53 IL# PE#QQR 53 albinterferon alfa 2b 53 GAP #B# 53 Memryte 53 Teriflunomide 53 motesanib 53 replicon 53 phase IIa 53 Kevetrin ™ 53 Randomized Phase 53 celgosivir 53 herpetic keratitis 53 darapladib 53 SRT# [003] 53 LymphoStat B belimumab 53 Atiprimod 53 syngeneic 53 Cinryze ™ 53 Copegus ribavirin 53 Epratuzumab 53 Phase III Clinical Trial 53 Gattex 53 hepatoma 53 Relivar 53 hGH CTP 53 JZP 53 Preclinical studies 53 Zoraxel 53 lapatinib Tykerb 53 DUROS 53 ulimorelin 53 siRNA therapeutic 53 pharmacokinetic characteristics 53 paclitaxel Taxol ® 53 Annexin V 53 highly selective endothelin 53 OvaRex ® MAb 53 preclinical studies 53 Phase #b/#a clinical 53 ORENCIA R 53 Kahalalide F 53 intravesical instillation 53 EGS# 53 Ambrisentan 53 Arikace 53 Bevirimat 53 ARRY 53 ozarelix 53 UVIDEM 53 stated Michelle Berrey 53 EXPAREL TM 53 TNFerade 53 Davanat 53 interferon alfa 53 ZFP TF 53 rALLy clinical trial 53 Dalbavancin 53 Zenvia ™ 53 mg kg dose 53 lupus nephritis 53 immunomodulatory 53 Pancreate 53 Phase #/#a trial 53 humanized monoclonal 53 oxidative stress inducer 53 GEM OS2 53 topically administered 53 Caprospinol 53 therapeutic monoclonal antibody 53 Evoltra ® 53 Allovectin 7 53 Ereska 53 antiviral activity 53 Tasimelteon 53 ISTODAX 53 flavopiridol 53 GATTEX 53 MVA BN 53 ARC# [001] 53 Neugene 53 Aerosurf 53 ALKS 53 GVAX ® 53 CK # 53 CYT# QbG# 53 Alfacell proprietary ribonuclease 53 HCV protease inhibitors 53 CLORETAZINE TM VNP#M 53 vascular disrupting agents 53 superficial bladder cancer 53 tezampanel NGX# 53 meropenem 53 LibiGel ® 53 PEGylated interferon 53 PI3K/mTOR 53 Immunotherapeutic 53 AEZS 53 platelet inhibitor